Table 2.
Outcomes after 12 months of monoclonal antibody therapy.
| Characteristics | All monoclonal antibody therapies n = 188 | Omalizumab n = 34 | Mepolizumab n = 96 | Reslizumab n = 38 | Benralizumab n = 20 | Comparison of the 4 treatment groups, p-value |
|---|---|---|---|---|---|---|
| Laboratory parameters | ||||||
| Level of eosinophils (cells/μL) median (IQR) | 100 (0–100) | 200 (100–500) | 100 (0–100) | 0 (0–100) | 0 (0–0) | 0.000 |
| Respiratory functional parameters | ||||||
| FEV 1, %, median (IQR) | 84 (71–97) | 91 (77.6–103) | 86 (73–97) | 79 (66–91) | 78 (60–94) | 0.071 |
| FeNO ppb, median (IQR) | 33.1 (23.8–51.7) | 32.6 (11.7–79.4) | 32 (18.7–69.5) | 33.25 (26.6–50.4) | 38 (32–49) | 0.964 |
| Asthma control parameters | ||||||
| ACT, median (IQR) | 21 (18–24) | 21.5 (19–24) | 21 (19–24) | 22 (19–23) | 21 (16.5–24.5) | 0.969 |
| Exacerbations/year, median (IQR) | 0 (0–1) | 0 (0–1) | 0 (0–1) | 0 (0–0) | 0 (0–1) | 0.845 |
| Hospital admissions/year, median (IQR) | 0 (0–1) | 0 (0–0) | 0 (0–0) | 0 (0–0) | 0 (0–1) | 0.352 |
n, number of patients; IQR, interquartile range; FEV1, forced expiratory volume in the first second; FeNO, fractional exhaled nitric oxide; ACT, asthma control test.